W
Wolf H. Fridman
Researcher at University of Paris
Publications - 551
Citations - 60835
Wolf H. Fridman is an academic researcher from University of Paris. The author has contributed to research in topics: Immune system & Receptor. The author has an hindex of 97, co-authored 525 publications receiving 48713 citations. Previous affiliations of Wolf H. Fridman include Queen Elizabeth Hospital Birmingham & Pasteur Institute.
Papers
More filters
Journal ArticleDOI
Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid FcγRII Expressing Tumor Cells
Maya Ran,Adit Ben-Baruch Langer,Ilan Eliassi,Ofrah Gohar,Bosmat Gonen,Serge Gradsztajn,Wolf H. Fridman,Jean-Luc Teillaud,Isaac P. Witz +8 more
TL;DR: The possibility that Fc gamma RII expressing tumor cells could interfere with the immune system was tested and it was found that aggregated mouse IgG (as well as IgGl) could stimulate the proliferation of the T cell hybridoma (T2D4) and other Fc Gamma R II expressing T cells.
Posted ContentDOI
Comprehensive evaluation of computational cell-type quantification methods for immuno-oncology
Gregor Sturm,Francesca Finotello,Florent Petitprez,Jitao David Zhang,Jan Baumbach,Wolf H. Fridman,Markus List,Tatsiana Aneichyk +7 more
TL;DR: Sturm et al. as mentioned in this paper developed a systematic approach for benchmarking such computational methods and assessed the accuracy of tools at estimating nine different immune- and stromal cells from bulk RNA-seq samples.
Journal ArticleDOI
Two Distinct Regions of the Mouse β FcγR Gene Control Its Transcription
TL;DR: It is shown, by using two cell lines representative of B and mast cells, that different promoter fragments determine, in these two cell types, the transcription of the β FcγR gene.
Journal ArticleDOI
Presence of in vivo-activated T-cells expressing HLA-DR molecules and IL-2 receptors in peripheral blood of patients with nasopharyngeal carcinoma.
TL;DR: PBL from NPC patients exhibited a normal proliferative response to phytohemagglutinin and Concanavalin A (Con A) and an increased response to pokeweed mitogen (PWM), and a lack of cytotoxicity against an EBV‐transformed B‐cell line cannot be explained by an impairment of IL‐2 secretion, and is probably a result of the presence of high numbers of OKT8 suppressor T cells.
Journal ArticleDOI
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS)
Claire Mathiot,Jean-Yves Mary,Eric Tartour,Thierry Facon,Mathieu Monconduit,Bernard Grosbois,J. P. Pollet,J. L. Michaux,L. Euller Ziegler,Catherine Sautes,Régis Bataille,Wolf H. Fridman +11 more
TL;DR: A low sCD16 level in MGUS indicated a high likelihood of rapid evolution to multiple myeloma, and soluble IL‐6R did not appear to be discriminant in this study.